Alzheimer's disease is characterized by cholinergic dysfunction and neuroinflammation, with acetylcholinesterase and monoacylglycerol lipase emerging as important therapeutic targets. The gene discussed is MGLL; the disease is early-onset autosomal dominant Alzheimer disease.